Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …

Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10%
in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk …

Pancreatic cancer is an increasingly common cause of cancer mortality with a tight
correspondence between disease mortality and incidence. Furthermore, it is usually …

PURPOSE The aim of this work was to provide an update to the ASCO guideline on
metastatic pancreatic cancer pertaining to recommendations for therapy options after first …

Improvements in the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC)
have lagged behind advances made in the treatment of many other malignancies over the …

Pancreatic cancer is one of the most lethal solid organ tumors. Due to the rising incidence,
late diagnosis, and limited treatment options, it is expected to be the second leading cause …

Thanks to the development of modern chemotherapeutic regimens, survival after surgery for
pancreatic ductal adenocarcinoma (PDAC) has improved and pancreatologists worldwide …

Importance Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) and
gemcitabine plus nanoparticle albumin-bound (nab)–paclitaxel (GA) are first-line …

Background Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is
approved for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) …

Recent innovations in the next-generation sequencing technologies have unveiled that the
accumulation of genetic alterations results in the transformation of normal cells into cancer …